Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
These experiments make it clear
2023-11-22
These experiments make it clear that one can study the effect of antimalaria drugs that target the DHFR enzyme of P. falciparum by transferring the malaria enzyme into S. cerevisiae. The ease of growth and manipulation of the yeast make it easy to measure the sensitivity of any particular dhfr allel
-
Regarding progression free survival analyzing clinical trial
2023-11-22
Regarding progression free-survival, analyzing 12 clinical trials, we demonstrated that the use of antiangiogenic treatment results in a statistically longer PFS with a pooled HR of 0.76 (95% CI 0.65–0.89, pIon Channel Compound Library of improvement of PFS only is that after antiangiogenic therapy
-
br Small molecule homoisoflavonoid in combination with anti
2023-11-22
Small molecule homoisoflavonoid in combination with anti-VEGF therapy Basavarajappa et al. [11] reported a new synthetic homoisoflavonoid compound, SH-11037 by modifying the structure of naturally occurring homoisoflavonoid cremastranone. SH-11037 exhibited promising inhibition of human retinal m
-
The excellent safety profile of solanezumab and encouraging
2023-11-22
The excellent safety profile of solanezumab and encouraging trends in the exploratory analyses in mild AD led to its inclusion in two secondary prevention trials, which are continuing in the hope that earlier intervention may yield more substantial benefit. The A4 study (NCT02008357) started in Febr
-
CCT251545 Interestingly metabolic dysfunction is also observ
2023-11-22
Interestingly, metabolic dysfunction is also observed in amyotrophic lateral sclerosis (ALS). Patients and mouse models of familial ALS exhibit higher levels of resting CCT251545 expenditure and lower fat-free mass, indicating a hypermetabolic phenotype. Lim et al. (2012) found that reducing AMPK ac
-
br Results br Discussion Using primarily an electrophysiolog
2023-11-22
Results Discussion Using primarily an electrophysiological analysis of dysbindin-deficient hippocampal neurons in cultures and slices, we have uncovered a previously unreported role for dysbindin in enhancing CA3–CA1 AMPAR-mediated transmission. An earlier study, however, has reported a reduc
-
In glaucoma the primary retinal defect appears
2023-11-21
In glaucoma, the primary retinal defect appears in the GCL, whereas the other retinal layers appear normal (Kendell et al., 1995). In the current work, chronic elevation of IOP induced RGC apoptosis, especially in the GCL, and α2 adrenergic treatment reduced RGC apoptosis. Various studies have repor
-
It is reported that Adiponectin is able to suppress NF
2023-11-21
It is reported that Adiponectin is able to suppress NF-κB pathway, and Bcr-Abl fusion oncoprotein in CML activates NF-κB by stimulating its nuclear translocation and also by enhancing its transactivation function [25], [26]. Therefore, it is tempting to hypothesize that NF-κB pathway might be involv
-
These results from the present
2023-11-21
These results from the present study are summarized in Table 1. Eight drugs (doxorubicin, epirubicin, daunorubicin, idarubicin, irinotecan, imatinib, sunitinib and gefitinib) inhibited 5-HT-induced 5-HT3A and 5-HT3AB currents; three (irinotecan, topotecan and mitoxantrone) showed different responses
-
Oxipurinol br Materials and methods br Results br Discussion
2023-11-21
Materials and methods Results Discussions Diabetes is mainly divided into Type 1 diabetes and Type 2 diabetes [16]. Type 2 diabetes, featured by insulin resistance, results from environmental factors and poor eating habits [2]. Type 2 diabetes accounts for more than 95% of the diabetic pati
-
In conclusion AXL overexpression preexisted
2023-11-21
In conclusion, AXL overexpression preexisted in a subgroup of treatment-naive lung adenocarcinoma specimens harboring an activating EGFR mutation or in those with wild-type EGFR. Anti-AXL therapeutics delivered up front in combination with the EGFR inhibitor might overcome intrinsic or acquired resi
-
br Results br Discussion The
2023-11-21
Results Discussion The A. nidulans Aurora kinase displays diverse locations during mitosis and we show here that it also locates to hyphal regions where septa subsequently form, to the septal pore region of newly formed septa and displays a Dihydro-β-erythroidine hydrobromide receptor specifi
-
br Materials and methods br Results and discussion In our
2023-11-21
Materials and methods Results and discussion In our previous studies (Matarneh et al., 2017), mitochondria were mechanically disrupted and separated into supernatant and pellet fractions by centrifugation. The causative agent for enhnced glycolytic flux was shown to be a protein that resides i
-
From an historical perspective ligands for GPCRs adrenaline
2023-11-21
From an historical perspective, ligands for GPCRs (adrenaline, serotonin, Phosphatase Inhibitor Cocktail 1 (100X in DMSO) or morphine, to name a few) have been identified before their receptor counterparts, at a time when the concept of receptor itself was controversial [15]. Although many cognate
-
In conclusion we report that the widely prescribed drug
2023-11-21
In conclusion, we report that the widely prescribed drug VPA exerts therapeutic effects on optic nerve demyelination and retinal degeneration in a mouse model of MS. Our findings raise an interesting possibility that combination therapy of VPA and ASK1 inhibition may be useful for treatment of autoi
15545 records 211/1037 page Previous Next First page 上5页 211212213214215 下5页 Last page